A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer
Bastiaannet E (1), Charman J (2), Johannesen TB (3), Schrodi S (4), Siesling S (5), van Eycken L (6), Walsh PM (7), Audisio RA (8), Boelens PG (1), Rubio IT (9), Jones N (10), Lewis J (10), van de Velde CJH (11).
(1) Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
(2) National Cancer Registration and Analysis Service, Public Health England, Birmingham, United Kingdom.
(3) Cancer Registry of Norway, Oslo, Norway.
(4) Munich Cancer Registry of the Munich Tumour Centre, Institute of Medical Information Processing, Biometry and Epidemiology, University Hospital of Munich, Ludwig-Maximilians-University, Munich, Germany.
(5) Netherlands Cancer Registry, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands; MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands.
(6) Belgian Cancer Registry, Brussels, Belgium.
(7) National Cancer Registry, Cork, Ireland.
(8) University of Liverpool, St Helens Teaching Hospital, St Helens, United Kingdom.
(9) Breast Surgical Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
(10) AstraZeneca, Cambridge, United Kingdom.
(11) Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
Magazine: Clinical Breast Cancer
Date: Nov 29, 2017Mammary Pathology Area
Despite guideline recommendations, reports suggest that a proportion of patients with hormone receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC) might not receive endocrine therapy.
The aims of this study were to estimate the proportion of postmenopausal patients with an initial (primary) diagnosis of HR-positive LA/MBC in Europe, and to assess the administration of endocrine treatment in these patients.
MATERIALS AND METHODS:
Fourteen national and regional cancer registries across Europe were invited to participate in this observational study. Six registries each provided anonymized clinical information on > 5000 postmenopausal women with breast cancer diagnosed between January 2000 and December 2014, including age at diagnosis, estrogen and/or progesterone receptor status, disease stage, and receipt of endocrine therapy. The proportion of patients with an initial diagnosis of HR-positive LA/MBC and, of these, the proportion who received endocrine therapy, was calculated.
Registries from Belgium, England, Ireland, Norway, The Netherlands, and Munich, Germany provided data. In total, 316,680 postmenopausal women were diagnosed with breast cancer, including 244,268 with known HR status and disease stage.
Of these patients, 19,002 (7.8%) had a primary diagnosis of HR-positive LA/MBC. This proportion ranged from 5.4% (N = 4484) in England to 12.7% (N = 4085) in Germany. Most of these patients (n = 14,157; 74.5%) received endocrine treatment, ranging from 55.5% (n = 445) in Norway to 88.1% (n = 443) in Belgium.
These results indicate that a sizeable proportion of postmenopausal patients in Europe received a primary diagnosis of HR-positive LA/MBC, and that almost three-quarters received subsequent endocrine therapy as per guideline recommendations.
CITA DEL ARTÍCULO Clin Breast Cancer. 2017 Nov 29. pii: S1526-8209(17)30728-0. doi: 10.1016/j.clbc.2017.11.019
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.